These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24142600)

  • 61. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Detemir vs Glargine: Comparison of Inpatient Glycemic Control.
    Capson J; Cade K; Avanesyan A
    J Am Osteopath Assoc; 2019 Feb; 119(2):89-95. PubMed ID: 30688354
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intensification of diabetes treatment with long-acting insulin shows no benefit over other diabetes treatment.
    Wainstein J; Leibovitz E; Segal T; Gavish D
    Isr Med Assoc J; 2011 Sep; 13(9):537-41. PubMed ID: 21991713
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current status of insulin degludec in type 1 and type 2 diabetes based on randomized and observational trials.
    Preumont V; Buysschaert M
    Diabetes Metab; 2020 Apr; 46(2):83-88. PubMed ID: 31055056
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus.
    Herrmann BL; Kasser C; Keuthage W; Huptas M; Dette H; Klute A
    Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):210-3. PubMed ID: 23512415
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Madenidou AV; Paschos P; Karagiannis T; Katsoula A; Athanasiadou E; Kitsios K; Bekiari E; Matthews DR; Tsapas A
    Ann Intern Med; 2018 Aug; 169(3):165-174. PubMed ID: 29987326
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes.
    Makino H; Tanaka A; Hosoda H; Koezuka R; Tochiya M; Ohata Y; Tamanaha T; Miyamoto Y; Kangawa K; Kishimoto I
    Diabet Med; 2016 Dec; 33(12):1737-1743. PubMed ID: 27150701
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Long-term evaluation of patients with type 1 diabetes mellitus treated with insulin glargine].
    Haladová I; Lacigová S; Cechurová D; Jankovec Z; Krcma M; Rusavý Z
    Vnitr Lek; 2009 Nov; 55(11):1016-21. PubMed ID: 20017431
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
    Oishi M; Abe N; Yokoyama H; Kuribayashi N; Tomonaga O; Matoba K; Kobayashi M;
    J Int Med Res; 2012; 40(2):787-97. PubMed ID: 22613444
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
    Idris I; Gordon J; Tilling C; Vora J
    J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Re: trial comparing insulin detemir with insulin glargine.
    Swinnen S; Holleman F
    Clin Ther; 2009 May; 31(5):1124-5; author reply 1125-6. PubMed ID: 19539113
    [No Abstract]   [Full Text] [Related]  

  • 75. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
    Levin PA; Mersey JH; Zhou S; Bromberger LA
    Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
    Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
    Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin.
    Dailey GE; Gao L; Aurand L; Garg SK
    Diabetes Obes Metab; 2013 Dec; 15(12):1085-92. PubMed ID: 23683002
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):129-37. PubMed ID: 20137765
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.